Skip to main content

Advertisement

SpringerLink
Log in

Update on parathyroid carcinoma

  • Review
  • Published:
Journal of Endocrinological Investigation Aims and scope Submit manuscript

Abstract

Introduction

Parathyroid carcinoma (PC) is a rare endocrine disorder, commonly causing severe primary hyperparathyroidism (PHPT). PC is mainly a sporadic disease, but it may occur in familial PHPT. Patients with PC usually present markedly elevated serum calcium and PTH. The clinical features are mostly due to the effects of the excessive secretion of PTH rather than to the spread of tumor. At times, the diagnosis can be difficult.

Purpose

The aim of this work is to review the available data on PC, and focus its molecular pathogenesis and the clinical utility of CDC73 genetic testing and immunostaining of its product, parafibromin. The pathological diagnosis of PC is restricted to lesions showing unequivocal growth into adjacent tissues or metastasis. Inactivating mutations of the cell division cycle 73 (CDC73) gene have been identified in up to 70 % of apparently sporadic PC and in one-third are germline. Loss of parafibromin immunostaining has been shown in most PC. The association of CDC73 mutations and loss of parafibromin predicts a worse clinical outcome and a lower overall 5- and 10-year survival.

Conclusions

The treatment of choice is the en bloc resection of the tumor. The course of PC is variable; most patients have local recurrences or distant metastases and die from unmanageable hypercalcemia.

This is a preview of subscription content, log in via an institution to check access.

Access this article

Log in via an institution

Price excludes VAT (USA)
Tax calculation will be finalised during checkout.

Instant access to the full article PDF.

Institutional subscriptions

Fig. 1
Fig. 2
Fig. 3
Fig. 4

Similar content being viewed by others

References

  1. Marcocci C, Cetani F, Rubin MR, Silverberg SJ, Pinchera A, Bilezikian JP (2008) Parathyroid carcinoma. J Bone Miner Res 23(12):1869–1880

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  2. Cetani F, Marcocci C (2015) Parathyroid carcinoma. In: Bilezikian JP, Marcus R, Levine MA, Marcocci C, Silverberg SJ, J.T. PJ (eds) The parathyroids. Basic and Clinical concepts. vol 1. 3rd edn. Elsevier, Waltham. pp 409–421

  3. Wilkins BJ, Lewis JS Jr (2009) Non-functional parathyroid carcinoma: a review of the literature and report of a case requiring extensive surgery. Head Neck Pathol 3(2):140–149. doi:10.1007/s12105-009-0115-4

    Article  PubMed  PubMed Central  Google Scholar 

  4. Harari A, Waring A, Fernandez-Ranvier G, Hwang J, Suh I, Mitmaker E, Shen W, Gosnell J, Duh QY, Clark O (2011) Parathyroid carcinoma: a 43-year outcome and survival analysis. J Clin Endocrinol Metab 96(12):3679–3686

    Article  CAS  PubMed  Google Scholar 

  5. Fernandez-Ranvier GG, Jensen K, Khanafshar E, Quivey JM, Glastonbury C, Kebebew E, Duh QY, Clark OH (2007) Nonfunctioning parathyroid carcinoma: case report and review of literature. Endocr Pract 13(7):750–757 (T813482448232M1H [pii])

    Article  PubMed  Google Scholar 

  6. Cetani F, Frustaci G, Torregrossa L, Magno S, Basolo F, Campomori A, Miccoli P, Marcocci C (2015) A nonfunctioning parathyroid carcinoma misdiagnosed as a follicular thyroid nodule. World J Surg Oncol 13:270. doi:10.1186/s12957-015-0672-9

    Article  PubMed  PubMed Central  Google Scholar 

  7. Boyle NH, Ogg CS, Hartley RB, Owen WJ (1999) Parathyroid carcinoma secondary to prolonged hyperplasia in chronic renal failure and in coeliac disease. Eur J Surg Oncol 25(1):100–103

    CAS  PubMed  Google Scholar 

  8. Fallah M, Kharazmi E, Sundquist J, Hemminki K (2011) Nonendocrine cancers associated with benign and malignant parathyroid tumors. J Clin Endocrinol Metab 96(7):E1108–E1114. doi:10.1210/jc.2011-0099

    Article  PubMed  Google Scholar 

  9. Marx SJ, Simonds WF, Agarwal SK, Burns AL, Weinstein LS, Cochran C, Skarulis MC, Spiegel AM, Libutti SK, Alexander HR Jr, Chen CC, Chang R, Chandrasekharappa SC, Collins FS (2002) Hyperparathyroidism in hereditary syndromes: special expressions and special managements. J Bone Miner Res 17(Suppl 2):N37–N43

    CAS  PubMed  Google Scholar 

  10. Newey PJ, Bowl MR, Cranston T, Thakker RV (2010) Cell division cycle protein 73 homolog (CDC73) mutations in the hyperparathyroidism-jaw tumor syndrome (HPT-JT) and parathyroid tumors. Hum Mutat 31(3):295–307

    Article  CAS  PubMed  Google Scholar 

  11. Bradley KJ, Hobbs MR, Buley ID, Carpten JD, Cavaco BM, Fares JE, Laidler P, Manek S, Robbins CM, Salti IS, Thompson NW, Jackson CE, Thakker RV (2005) Uterine tumours are a phenotypic manifestation of the hyperparathyroidism-jaw tumour syndrome. J Intern Med 257(1):18–26. doi:10.1111/j.1365-2796.2004.01421.x

    Article  CAS  PubMed  Google Scholar 

  12. Wassif WS, Moniz CF, Friedman E, Wong S, Weber G, Nordenskjold M, Peters TJ, Larsson C (1993) Familial isolated hyperparathyroidism: a distinct genetic entity with an increased risk of parathyroid cancer. J Clin Endocrinol Metab 77(6):1485–1489

    CAS  PubMed  Google Scholar 

  13. Simonds WF, James-Newton LA, Agarwal SK, Yang B, Skarulis MC, Hendy GN, Marx SJ (2002) Familial isolated hyperparathyroidism: clinical and genetic characteristics of 36 kindreds. Medicine (Baltimore) 81(1):1–26

    Article  Google Scholar 

  14. del Pozo C, Garcia-Pascual L, Balsells M, Barahona MJ, Veloso E, Gonzalez C, Anglada-Barcelo J (2011) Parathyroid carcinoma in multiple endocrine neoplasia type 1. Case report and review of the literature. Hormones (Athens) 10(4):326–331

  15. Jenkins PJ, Satta MA, Simmgen M, Drake WM, Williamson C, Lowe DG, Britton K, Chew SL, Thakker RV, Besser GM (1997) Metastatic parathyroid carcinoma in the MEN2A syndrome. Clin Endocrinol 47(6):747–751

    Article  CAS  Google Scholar 

  16. Cetani F, Pardi E, Borsari S, Marcocci C (2011) Molecular pathogenesis of primary hyperparathyroidism. J Endocrinol Invest 34(7 Suppl):35–39 (8004 [pii])

    CAS  PubMed  Google Scholar 

  17. Carpten JD, Robbins CM, Villablanca A, Forsberg L, Presciuttini S, Bailey-Wilson J, Simonds WF, Gillanders EM, Kennedy AM, Chen JD, Agarwal SK, Sood R, Jones MP, Moses TY, Haven C, Petillo D, Leotlela PD, Harding B, Cameron D, Pannett AA, Hoog A, Heath H 3rd, James-Newton LA, Robinson B, Zarbo RJ, Cavaco BM, Wassif W, Perrier ND, Rosen IB, Kristoffersson U, Turnpenny PD, Farnebo LO, Besser GM, Jackson CE, Morreau H, Trent JM, Thakker RV, Marx SJ, Teh BT, Larsson C, Hobbs MR (2002) HRPT2, encoding parafibromin, is mutated in hyperparathyroidism-jaw tumor syndrome. Nat Genet 32(4):676–680

    Article  CAS  PubMed  Google Scholar 

  18. Howell VM, Haven CJ, Kahnoski K, Khoo SK, Petillo D, Chen J, Fleuren GJ, Robinson BG, Delbridge LW, Philips J, Nelson AE, Krause U, Hammje K, Dralle H, Hoang-Vu C, Gimm O, Marsh DJ, Morreau H, Teh BT (2003) HRPT2 mutations are associated with malignancy in sporadic parathyroid tumours. J Med Genet 40(9):657–663

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  19. Cetani F, Pardi E, Borsari S, Viacava P, Dipollina G, Cianferotti L, Ambrogini E, Gazzerro E, Colussi G, Berti P, Miccoli P, Pinchera A, Marcocci C (2004) Genetic analyses of the HRPT2 gene in primary hyperparathyroidism: germline and somatic mutations in familial and sporadic parathyroid tumors. J Clin Endocrinol Metab 89(11):5583–5591

    Article  CAS  PubMed  Google Scholar 

  20. Simonds WF, Robbins CM, Agarwal SK, Hendy GN, Carpten JD, Marx SJ (2004) Familial isolated hyperparathyroidism is rarely caused by germline mutation in HRPT2, the gene for the hyperparathyroidism-jaw tumor syndrome. J Clin Endocrinol Metab 89(1):96–102

    Article  CAS  PubMed  Google Scholar 

  21. Warner J, Epstein M, Sweet A, Singh D, Burgess J, Stranks S, Hill P, Perry-Keene D, Learoyd D, Robinson B, Birdsey P, Mackenzie E, Teh BT, Prins JB, Cardinal J (2004) Genetic testing in familial isolated hyperparathyroidism: unexpected results and their implications. J Med Genet 41(3):155–160

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  22. Villablanca A, Calender A, Forsberg L, Hoog A, Cheng JD, Petillo D, Bauters C, Kahnoski K, Ebeling T, Salmela P, Richardson AL, Delbridge L, Meyrier A, Proye C, Carpten JD, Teh BT, Robinson BG, Larsson C (2004) Germline and de novo mutations in the HRPT2 tumour suppressor gene in familial isolated hyperparathyroidism (FIHP). J Med Genet 41(3):e32

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  23. Bradley KJ, Cavaco BM, Bowl MR, Harding B, Cranston T, Fratter C, Besser GM, Conceicao Pereira M, Davie MW, Dudley N, Leite V, Sadler GP, Seller A, Thakker RV (2006) Parafibromin mutations in hereditary hyperparathyroidism syndromes and parathyroid tumours. Clin Endocrinol 64(3):299–306. doi:10.1111/j.1365-2265.2006.02460.x

    Article  CAS  Google Scholar 

  24. Mizusawa N, Uchino S, Iwata T, Tsuyuguchi M, Suzuki Y, Mizukoshi T, Yamashita Y, Sakurai A, Suzuki S, Beniko M, Tahara H, Fujisawa M, Kamata N, Fujisawa K, Yashiro T, Nagao D, Golam HM, Sano T, Noguchi S, Yoshimoto K (2006) Genetic analyses in patients with familial isolated hyperparathyroidism and hyperparathyroidism-jaw tumour syndrome. Clin Endocrinol 65(1):9–16. doi:10.1111/j.1365-2265.2006.02534.x

    Article  CAS  Google Scholar 

  25. Guarnieri V, Scillitani A, Muscarella LA, Battista C, Bonfitto N, Bisceglia M, Minisola S, Mascia ML, D’Agruma L, Cole DE (2006) Diagnosis of parathyroid tumors in familial isolated hyperparathyroidism with HRPT2 mutation: implications for cancer surveillance. J Clin Endocrinol Metab 91(8):2827–2832. doi:10.1210/jc.2005-1239

    Article  CAS  PubMed  Google Scholar 

  26. Kelly TG, Shattuck TM, Reyes-Mugica M, Stewart AF, Simonds WF, Udelsman R, Arnold A, Carpenter TO (2006) Surveillance for early detection of aggressive parathyroid disease: carcinoma and atypical adenoma in familial isolated hyperparathyroidism associated with a germline HRPT2 mutation. J Bone Miner Res 21(10):1666–1671. doi:10.1359/jbmr.060702

    Article  CAS  PubMed  Google Scholar 

  27. Korpi-Hyovalti E, Cranston T, Ryhanen E, Arola J, Aittomaki K, Sane T, Thakker RV, Schalin-Jantti C (2014) CDC73 intragenic deletion in familial primary hyperparathyroidism associated with parathyroid carcinoma. J Clin Endocrinol Metab 99(9):3044–3048. doi:10.1210/jc.2014-1481

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  28. Shattuck TM, Valimaki S, Obara T, Gaz RD, Clark OH, Shoback D, Wierman ME, Tojo K, Robbins CM, Carpten JD, Farnebo LO, Larsson C, Arnold A (2003) Somatic and germ-line mutations of the HRPT2 gene in sporadic parathyroid carcinoma. N Engl J Med 349(18):1722–1729

    Article  CAS  PubMed  Google Scholar 

  29. Cetani F, Ambrogini E, Viacava P, Pardi E, Fanelli G, Naccarato AG, Borsari S, Lemmi M, Berti P, Miccoli P, Pinchera A, Marcocci C (2007) Should parafibromin staining replace HRTP2 gene analysis as an additional tool for histologic diagnosis of parathyroid carcinoma? Eur J Endocrinol/Eur Feder Endocrine Soc 156(5):547–554

    Article  CAS  Google Scholar 

  30. Haven CJ, van Puijenbroek M, Tan MH, Teh BT, Fleuren GJ, van Wezel T, Morreau H (2007) Identification of MEN1 and HRPT2 somatic mutations in paraffin-embedded (sporadic) parathyroid carcinomas. Clin Endocrinol 67(3):370–376

    Article  CAS  Google Scholar 

  31. Cetani F, Pardi E, Ambrogini E, Banti C, Viacava P, Borsari S, Bilezikian JP, Pinchera A, Marcocci C (2008) Hyperparathyroidism 2 gene (HRPT2, CDC73) and parafibromin studies in two patients with primary hyperparathyroidism and uncertain pathological assessment. J Endocrinol Invest 31(10):900–904 (5015 [pii])

    Article  CAS  PubMed  Google Scholar 

  32. Guarnieri V, Battista C, Muscarella LA, Bisceglia M, de Martino D, Baorda F, Maiello E, D’Agruma L, Chiodini I, Clemente C, Minisola S, Romagnoli E, Corbetta S, Viti R, Eller-Vainicher C, Spada A, Iacobellis M, Malavolta N, Carella M, Canaff L, Hendy GN, Cole DE, Scillitani A (2012) CDC73 mutations and parafibromin immunohistochemistry in parathyroid tumors: clinical correlations in a single-centre patient cohort. Cell Oncol (Dordr) 35(6):411–422

    Article  CAS  PubMed  Google Scholar 

  33. Wang O, Wang C, Nie M, Cui Q, Guan H, Jiang Y, Li M, Xia W, Meng X, Xing X (2012) Novel HRPT2/CDC73 gene mutations and loss of expression of parafibromin in Chinese patients with clinically sporadic parathyroid carcinomas. PLoS One 7(9):e45567

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  34. Bricaire L, Odou MF, Cardot-Bauters C, Delemer B, North MO, Salenave S, Vezzosi D, Kuhn JM, Murat A, Caron P, Sadoul JL, Silve C, Chanson P, Barlier A, Clauser E, Porchet N, Groussin L (2013) Frequent large germline HRPT2 deletions in a French National cohort of patients with primary hyperparathyroidism. J Clin Endocrinol Metab 98(2):E403–E408

    Article  CAS  PubMed  Google Scholar 

  35. Cetani F, Banti C, Pardi E, Borsari S, Viacava P, Miccoli P, Torregrossa L, Basolo F, Pelizzo MR, Rugge M, Pennelli G, Gasparri G, Papotti M, Volante M, Vignali E, Saponaro F, Marcocci C (2013) CDC73 mutational status and loss of parafibromin in the outcome of parathyroid cancer. Endocr Connect 2(4):186–195. doi:10.1530/EC-13-0046

  36. Yu W, McPherson JR, Stevenson M, van Eijk R, Heng HL, Newey P, Gan A, Ruano D, Huang D, Poon SL, Ong CK, van Wezel T, Cavaco B, Rozen SG, Tan P, Teh BT, Thakker RV, Morreau H (2015) Whole-exome sequencing studies of parathyroid carcinomas reveal novel PRUNE2 mutations, distinctive mutational spectra related to APOBEC-catalyzed DNA mutagenesis and mutational enrichment in kinases associated with cell migration and invasion. J Clin Endocrinol Metab 100(2):E360–E364. doi:10.1210/jc.2014-3238

    Article  CAS  PubMed  Google Scholar 

  37. Cavaco BM, Santos R, Felix A, Carvalho D, Lopes JM, Domingues R, Sirgado M, Rei N, Fonseca F, Santos JR, Sobrinho L, Leite V (2011) Identification of de novo germline mutations in the HRPT2 gene in two apparently sporadic cases with challenging parathyroid tumor diagnoses. Endocrine Pathol 22(1):44–52. doi:10.1007/s12022-011-9151-1

    Article  CAS  Google Scholar 

  38. Domingues R, Tomaz RA, Martins C, Nunes C, Bugalho MJ, Cavaco BM (2012) Identification of the first germline HRPT2 whole-gene deletion in a patient with primary hyperparathyroidism. Clin Endocrinol 76(1):33–38. doi:10.1111/j.1365-2265.2011.04184.x

    Article  CAS  Google Scholar 

  39. Enomoto K, Uchino S, Ito A, Watanabe S, Shibuya H, Enomoto Y, Noguchi S (2010) The surgical strategy and the molecular analysis of patients with parathyroid cancer. World J Surg 34(11):2604–2610. doi:10.1007/s00268-010-0618-x

    Article  PubMed  Google Scholar 

  40. Siu WK, Law CY, Lam CW, Mak CM, Wong GW, Ho AY, Ho KY, Loo KT, Chiu SC, Chow LT, Tong SF, Chan AY (2011) Novel nonsense CDC73 mutations in Chinese patients with parathyroid tumors. Fam Cancer 10(4):695–699. doi:10.1007/s10689-011-9466-6

    Article  PubMed  Google Scholar 

  41. Hewitt KM, Sharma PK, Samowitz W, Hobbs M (2007) Aberrant methylation of the HRPT2 gene in parathyroid carcinoma. Ann Otol Rhinol Laryngol 116(12):928–933

    Article  PubMed  Google Scholar 

  42. Krebs LJ, Shattuck TM, Arnold A (2005) HRPT2 mutational analysis of typical sporadic parathyroid adenomas. J Clin Endocrinol Metab 90(9):5015–5017

    Article  CAS  PubMed  Google Scholar 

  43. Yart A, Gstaiger M, Wirbelauer C, Pecnik M, Anastasiou D, Hess D, Krek W (2005) The HRPT2 tumor suppressor gene product parafibromin associates with human PAF1 and RNA polymerase II. Mol Cell Biol 25(12):5052–5060. doi:10.1128/MCB.25.12.5052-5060.2005

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  44. Hahn MA, Marsh DJ (2005) Identification of a functional bipartite nuclear localization signal in the tumor suppressor parafibromin. Oncogene 24(41):6241–6248. doi:10.1038/sj.onc.1208778

    Article  CAS  PubMed  Google Scholar 

  45. Bradley KJ, Bowl MR, Williams SE, Ahmad BN, Partridge CJ, Patmanidi AL, Kennedy AM, Loh NY, Thakker RV (2007) Parafibromin is a nuclear protein with a functional monopartite nuclear localization signal. Oncogene 26(8):1213–1221. doi:10.1038/sj.onc.1209893

    Article  CAS  PubMed  Google Scholar 

  46. Lin L, Czapiga M, Nini L, Zhang JH, Simonds WF (2007) Nuclear localization of the parafibromin tumor suppressor protein implicated in the hyperparathyroidism-jaw tumor syndrome enhances its proapoptotic function. Mol Cancer Res 5(2):183–193. doi:10.1158/1541-7786.MCR-06-0129

    Article  CAS  PubMed  Google Scholar 

  47. Hahn MA, Marsh DJ (2007) Nucleolar localization of parafibromin is mediated by three nucleolar localization signals. FEBS Lett 581(26):5070–5074. doi:10.1016/j.febslet.2007.09.050

    Article  CAS  PubMed  Google Scholar 

  48. Tan MH, Morrison C, Wang P, Yang X, Haven CJ, Zhang C, Zhao P, Tretiakova MS, Korpi-Hyovalti E, Burgess JR, Soo KC, Cheah WK, Cao B, Resau J, Morreau H, Teh BT (2004) Loss of parafibromin immunoreactivity is a distinguishing feature of parathyroid carcinoma. Clin Cancer Res Off J Am Assoc Cancer Res 10(19):6629–6637

    Article  CAS  Google Scholar 

  49. Juhlin C, Larsson C, Yakoleva T, Leibiger I, Leibiger B, Alimov A, Weber G, Hoog A, Villablanca A (2006) Loss of parafibromin expression in a subset of parathyroid adenomas. Endocr Relat Cancer 13(2):509–523

    Article  CAS  PubMed  Google Scholar 

  50. Juhlin CC, Villablanca A, Sandelin K, Haglund F, Nordenstrom J, Forsberg L, Branstrom R, Obara T, Arnold A, Larsson C, Hoog A (2007) Parafibromin immunoreactivity: its use as an additional diagnostic marker for parathyroid tumor classification. Endocr Relat Cancer 14(2):501–512

    Article  CAS  PubMed  Google Scholar 

  51. Howell VM, Gill A, Clarkson A, Nelson AE, Dunne R, Delbridge LW, Robinson BG, Teh BT, Gimm O, Marsh DJ (2009) Accuracy of combined protein gene product 9.5 and parafibromin markers for immunohistochemical diagnosis of parathyroid carcinoma. J Clin Endocrinol Metab 94(2):434–441

    Article  CAS  PubMed  Google Scholar 

  52. Kim HK, Oh YL, Kim SH, Lee DY, Kang HC, Lee JI, Jang HW, Hur KY, Kim JH, Min YK, Chung JH, Kim SW (2011) Parafibromin immunohistochemical staining to differentiate parathyroid carcinoma from parathyroid adenoma. Head Neck 34(2):201–206

    Article  PubMed  Google Scholar 

  53. Witteveen JE, Hamdy NA, Dekkers OM, Kievit J, van Wezel T, Teh BT, Romijn JA, Morreau H (2011) Downregulation of CASR expression and global loss of parafibromin staining are strong negative determinants of prognosis in parathyroid carcinoma. Modern Pathol Off J US Can Acad Pathol Inc 24(5):688–697

    CAS  Google Scholar 

  54. Starker LF, Svedlund J, Udelsman R, Dralle H, Akerstrom G, Westin G, Lifton RP, Bjorklund P, Carling T (2011) The DNA methylome of benign and malignant parathyroid tumors. Genes Chromosom Cancer 50(9):735–745

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  55. Costa-Guda J, Imanishi Y, Palanisamy N, Kawamata N, Phillip Koeffler H, Chaganti RS, Arnold A (2013) Allelic imbalance in sporadic parathyroid carcinoma and evidence for its de novo origins. Endocrine. doi:10.1007/s12020-013-9903-4

    PubMed  PubMed Central  Google Scholar 

  56. Verdelli C, Forno I, Vaira V, Corbetta S (2015) MicroRNA deregulation in parathyroid tumours suggests an embryonic signature. J Endocrinol Invest 38(4):383–388. doi:10.1007/s40618-014-0234-y

    Article  CAS  PubMed  Google Scholar 

  57. DeLellis RA (2005) Parathyroid carcinoma: an overview. Adv Anat Pathol 12(2):53–61 00125480-200503000-00003 [pii]

    Article  PubMed  Google Scholar 

  58. Schantz A, Castleman B (1973) Parathyroid carcinoma. A study of 70 cases. Cancer 31(3):600–605

    Article  CAS  PubMed  Google Scholar 

  59. Bondenson L, Grimelius L, DeLellis RA, Lloyd R, Akerstrom G, Larsson C, Arnold A, Eng C, Shane E, Bilezikian JP (2004) Parathyroid carcinoma. In: DeLellis RA, Lloyd RV, Heitz PU, Eng C (eds) Pathology and genetics. Tumors of Endocrine organs. WHO Classification of Tumours. IARC Press, Lyon, pp 124–127

  60. Delellis RA (2008) Challenging lesions in the differential diagnosis of endocrine tumors: parathyroid carcinoma. Endocrine Pathol 19(4):221–225. doi:10.1007/s12022-008-9050-2

    Article  CAS  Google Scholar 

  61. Apel RL (2002) The parathyroid glands. In: LiVolsi VA, Asa SL (eds) Endocrine pathology. Churchill Livingstone, Philadelphia, pp 103–147

    Google Scholar 

  62. Sandelin K, Tullgren O, Farnebo LO (1994) Clinical course of metastatic parathyroid cancer. World J Surg 18(4):594–598

    Article  CAS  PubMed  Google Scholar 

  63. Cetani F, Pardi E, Viacava P, Pollina GD, Fanelli G, Picone A, Borsari S, Gazzerro E, Miccoli P, Berti P, Pinchera A, Marcocci C (2004) A reappraisal of the Rb1 gene abnormalities in the diagnosis of parathyroid cancer. Clin Endocrinol 60(1):99–106 (1954 [pii])

    Article  CAS  Google Scholar 

  64. Bergero N, De Pompa R, Sacerdote C, Gasparri G, Volante M, Bussolati G, Papotti M (2005) Galectin-3 expression in parathyroid carcinoma: immunohistochemical study of 26 cases. Hum Pathol 36(8):908–914. doi:10.1016/j.humpath.2005.06.020

    Article  CAS  PubMed  Google Scholar 

  65. Fernandez-Ranvier GG, Khanafshar E, Tacha D, Wong M, Kebebew E, Duh QY, Clark OH (2009) Defining a molecular phenotype for benign and malignant parathyroid tumors. Cancer 115(2):334–344

    Article  PubMed  Google Scholar 

  66. Wang O, Wang CY, Shi J, Nie M, Xia WB, Li M, Jiang Y, Guan H, Meng XW, Xing XP (2012) Expression of Ki-67, galectin-3, fragile histidine triad, and parafibromin in malignant and benign parathyroid tumors. Chin Med J (Engl) 125(16):2895–2901

    CAS  Google Scholar 

  67. Shifrin A, LiVolsi V, Shifrin-Douglas S, Zheng M, Erler B, Matulewicz T, Davis J (2015) Primary and metastatic parathyroid malignancies: a rare or underdiagnosed condition? J Clin Endocrinol Metab 100(3):E478–E481. doi:10.1210/jc.2014-2760

    Article  CAS  PubMed  Google Scholar 

  68. Erickson LA, Jin L, Wollan P, Thompson GB, van Heerden JA, Lloyd RV (1999) Parathyroid hyperplasia, adenomas, and carcinomas: differential expression of p27Kip1 protein. Am J Surg Pathol 23(3):288–295

    Article  CAS  PubMed  Google Scholar 

  69. Gill AJ, Clarkson A, Gimm O, Keil J, Dralle H, Howell VM, Marsh DJ (2006) Loss of nuclear expression of parafibromin distinguishes parathyroid carcinomas and hyperparathyroidism-jaw tumor (HPT-JT) syndrome-related adenomas from sporadic parathyroid adenomas and hyperplasias. Am J Surg Pathol 30(9):1140–1149

    Article  PubMed  Google Scholar 

  70. Marcocci C, Cetani F (2011) Clinical practice. Primary hyperparathyroidism. N Engl J Med 365(25):2389–2397. doi:10.1056/NEJMcp1106636

    Article  CAS  PubMed  Google Scholar 

  71. Rubin MR, Silverberg SJ, D’Amour P, Brossard JH, Rousseau L, Sliney J Jr, Cantor T, Bilezikian JP (2007) An N-terminal molecular form of parathyroid hormone (PTH) distinct from hPTH(1 84) is overproduced in parathyroid carcinoma. Clin Chem 53(8):1470–1476. doi:10.1373/clinchem.2007.085506

    Article  CAS  PubMed  Google Scholar 

  72. Cavalier E, Daly AF, Betea D, Pruteanu-Apetrii PN, Delanaye P, Stubbs P, Bradwell AR, Chapelle JP, Beckers A (2010) The ratio of parathyroid hormone as measured by third- and second-generation assays as a marker for parathyroid carcinoma. J Clin Endocrinol Metab 95(8):3745–3749. doi:10.1210/jc.2009-2791

    Article  CAS  PubMed  Google Scholar 

  73. Caron P, Simonds WF, Maiza JC, Rubin M, Cantor T, Rousseau L, Bilezikian JP, Souberbielle JC, D’Amour P (2011) Nontruncated amino-terminal parathyroid hormone overproduction in two patients with parathyroid carcinoma: a possible link to HRPT2 gene inactivation. Clin Endocrinol 74(6):694–698. doi:10.1111/j.1365-2265.2011.04021.x

    Article  CAS  Google Scholar 

  74. Rubin MR, Bilezikian JP, Birken S, Silverberg SJ (2008) Human chorionic gonadotropin measurements in parathyroid carcinoma. Eur J Endocrinol/Eur Feder Endocrine Soc 159(4):469–474. doi:10.1530/EJE-08-0169

    Article  CAS  Google Scholar 

  75. Talat N, Schulte KM (2010) Clinical presentation, staging and long-term evolution of parathyroid cancer. Ann Surg Oncol 17(8):2156–2174. doi:10.1245/s10434-010-1003-6

    Article  PubMed  Google Scholar 

  76. Whitson BA, Broadie TA (2008) Preoperative ultrasound and nuclear medicine studies improve the accuracy in localization of adenoma in hyperparathyroidism. Surg Today 38(3):222–226. doi:10.1007/s00595-007-3612-7

    Article  PubMed  Google Scholar 

  77. Kwon JH, Kim EK, Lee HS, Moon HJ, Kwak JY (2013) Neck ultrasonography as preoperative localization of primary hyperparathyroidism with an additional role of detecting thyroid malignancy. Eur J Radiol 82(1):e17–e21. doi:10.1016/j.ejrad.2012.08.003

    Article  PubMed  Google Scholar 

  78. Sidhu PS, Talat N, Patel P, Mulholland NJ, Schulte KM (2011) Ultrasound features of malignancy in the preoperative diagnosis of parathyroid cancer: a retrospective analysis of parathyroid tumours larger than 15 mm. Eur Radiol 21(9):1865–1873. doi:10.1007/s00330-011-2141-3

    Article  PubMed  Google Scholar 

  79. Hunter GJ, Schellingerhout D, Vu TH, Perrier ND, Hamberg LM (2012) Accuracy of four-dimensional CT for the localization of abnormal parathyroid glands in patients with primary hyperparathyroidism. Radiology 264(3):789–795. doi:10.1148/radiol.12110852

    Article  PubMed  Google Scholar 

  80. Evangelista L, Sorgato N, Torresan F, Boschin IM, Pennelli G, Saladini G, Piotto A, Rubello D, Pelizzo MR (2011) FDG-PET/CT and parathyroid carcinoma: review of literature and illustrative case series. World J Clin Oncol 2(10):348–354. doi:10.5306/wjco.v2.i10.348

    Article  PubMed  PubMed Central  Google Scholar 

  81. Allen ME, Semrad A, Yang AD, Martinez SR (2013) Parathyroid carcinoma survival: improvements in the era of intact parathyroid hormone monitoring? Rare Tumors 5(1):e12. doi:10.4081/rt.2013.e12

    Article  PubMed  PubMed Central  Google Scholar 

  82. Busaidy NL, Jimenez C, Habra MA, Schultz PN, El-Naggar AK, Clayman GL, Asper JA, Diaz EM Jr, Evans DB, Gagel RF, Garden A, Hoff AO, Lee JE, Morrison WH, Rosenthal DI, Sherman SI, Sturgis EM, Waguespack SG, Weber RS, Wirfel K, Vassilopoulou-Sellin R (2004) Parathyroid carcinoma: a 22-year experience. Head Neck 26(8):716–726

    Article  PubMed  Google Scholar 

  83. Lee PK, Jarosek SL, Virnig BA, Evasovich M, Tuttle TM (2007) Trends in the incidence and treatment of parathyroid cancer in the United States. Cancer 109(9):1736–1741. doi:10.1002/cncr.22599

    Article  PubMed  Google Scholar 

  84. Sandelin K, Auer G, Bondeson L, Grimelius L, Farnebo LO (1992) Prognostic factors in parathyroid cancer: a review of 95 cases. World J Surg 16(4):724–731

    Article  CAS  PubMed  Google Scholar 

  85. Hundahl SA, Fleming ID, Fremgen AM, Menck HR (1999) Two hundred eighty-six cases of parathyroid carcinoma treated in the US between 1985–1995: a National Cancer Data Base Report. The American College of Surgeons Commission on Cancer and the American Cancer Society. Cancer 86(3):538–544. doi:10.1002/(SICI)1097-0142(19990801)86:3<538:AID-CNCR25>3.0.CO;2-K

    Article  CAS  PubMed  Google Scholar 

  86. Kebebew E (2001) Parathyroid carcinoma. Curr Treat Options Oncol 2(4):347–354

    Article  CAS  PubMed  Google Scholar 

  87. Schulte KM, Talat N, Miell J, Moniz C, Sinha P, Diaz-Cano S (2010) Lymph node involvement and surgical approach in parathyroid cancer. World J Surg 34(11):2611–2620. doi:10.1007/s00268-010-0722-y

    Article  PubMed  Google Scholar 

  88. Spinelli C, Bonadio AG, Berti P, Materazzi G, Miccoli P (2000) Cutaneous spreading of parathyroid carcinoma after fine needle aspiration cytology. J Endocrinol Invest 23(4):255–257

    Article  CAS  PubMed  Google Scholar 

  89. Rawat N, Khetan N, Williams DW, Baxter JN (2005) Parathyroid carcinoma. Br J Surg 92(11):1345–1353. doi:10.1002/bjs.5182

    Article  CAS  PubMed  Google Scholar 

  90. Wynne AG, van Heerden J, Carney JA, Fitzpatrick LA (1992) Parathyroid carcinoma: clinical and pathologic features in 43 patients. Medicine (Baltimore) 71(4):197–205

    Article  CAS  Google Scholar 

  91. Munson ND, Foote RL, Northcutt RC, Tiegs RD, Fitzpatrick LA, Grant CS, van Heerden JA, Thompson GB, Lloyd RV (2003) Parathyroid carcinoma: is there a role for adjuvant radiation therapy? Cancer 98(11):2378–2384. doi:10.1002/cncr.11819

    Article  PubMed  Google Scholar 

  92. Clayman GL, Gonzalez HE, El-Naggar A, Vassilopoulou-Sellin R (2004) Parathyroid carcinoma: evaluation and interdisciplinary management. Cancer 100(5):900–905. doi:10.1002/cncr.20089

    Article  PubMed  Google Scholar 

  93. Artinyan A, Guzman E, Maghami E, Al-Sayed M, D’Apuzzo M, Wagman L, Kim J (2008) Metastatic parathyroid carcinoma to the liver treated with radiofrequency ablation and transcatheter arterial embolization. J Clin Oncol 26(24):4039–4041. doi:10.1200/JCO.2007.15.9038

    Article  PubMed  Google Scholar 

  94. Tochio M, Takaki H, Yamakado K, Uraki J, Kashima M, Nakatsuka A, Takao M, Shimamoto A, Tarukawa T, Shimpo H, Takeda K (2010) A case report of 20 lung radiofrequency ablation sessions for 50 lung metastases from parathyroid carcinoma causing hyperparathyroidism. Cardiovasc Intervent Radiol 33(3):657–659. doi:10.1007/s00270-009-9730-4

    Article  PubMed  Google Scholar 

  95. Tong CV, Hussein Z, Noor NM, Mohamad M, Ng WF (2015) Use of denosumab in parathyroid carcinoma with refractory hypercalcemia. QJM Mon J Assoc Physicians 108(1):49–50. doi:10.1093/qjmed/hcu166

    Article  CAS  Google Scholar 

  96. Betea D, Bradwell AR, Harvey TC, Mead GP, Schmidt-Gayk H, Ghaye B, Daly AF, Beckers A (2004) Hormonal and biochemical normalization and tumor shrinkage induced by anti-parathyroid hormone immunotherapy in a patient with metastatic parathyroid carcinoma. J Clin Endocrinol Metab 89(7):3413–3420. doi:10.1210/jc.2003-031911

    Article  CAS  PubMed  Google Scholar 

  97. Horie I, Ando T, Inokuchi N, Mihara Y, Miura S, Imaizumi M, Usa T, Kinoshita N, Sekine I, Kamihara S, Eguchi K (2010) First Japanese patient treated with parathyroid hormone peptide immunization for refractory hypercalcemia caused by metastatic parathyroid carcinoma. Endocr J 57(4):287–292 (JST.JSTAGE/endocrj/K09E−283 [pii])

    Article  PubMed  Google Scholar 

  98. Schott M, Feldkamp J, Schattenberg D, Krueger T, Dotzenrath C, Seissler J, Scherbaum WA (2000) Induction of cellular immunity in a parathyroid carcinoma treated with tumor lysate-pulsed dendritic cells. Eur J Endocrinol/Eur Feder Endocrine Soc 142(3):300–306 (1420300 [pii])

    Article  CAS  Google Scholar 

  99. Peacock M, Bilezikian JP, Bolognese MA, Borofsky M, Scumpia S, Sterling LR, Cheng S, Shoback D (2011) Cinacalcet HCl reduces hypercalcemia in primary hyperparathyroidism across a wide spectrum of disease severity. J Clin Endocrinol Metab 96(1):E9–E18. doi:10.1210/jc.2010-1221

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  100. Saponaro F, Faggiano A, Grimaldi F, Borretta G, Brandi ML, Minisola S, Frasoldati A, Papini E, Scillitani A, Banti C, Prete MD, Vescini F, Gianotti L, Cavalli L, Romagnoli E, Colao A, Cetani F, Marcocci C (2013) Cinacalcet in the management of primary hyperparathyroidism: post marketing experience of an Italian multicentre group. Clin Endocrinol 79(1):20–26. doi:10.1111/cen.12108

    Article  CAS  Google Scholar 

  101. Silverberg SJ, Rubin MR, Faiman C, Peacock M, Shoback DM, Smallridge RC, Schwanauer LE, Olson KA, Klassen P, Bilezikian JP (2007) Cinacalcet hydrochloride reduces the serum calcium concentration in inoperable parathyroid carcinoma. J Clin Endocrinol Metab 92(10):3803–3808. doi:10.1210/jc.2007-0585

    Article  CAS  PubMed  Google Scholar 

Download references

Acknowledgments

The authors thank Dr. Liborio Torregrossa for preparing the histological images.

Author information

Authors and Affiliations

  1. University Hospital of Pisa, Endocrine Unit 2, Via Paradisa, 2, 56124, Pisa, Italy

    F. Cetani

  2. Department of Clinical and Experimental Medicine, University of Pisa, Endocrine Unit 2, Pisa, Italy

    E. Pardi & C. Marcocci

Authors
  1. F. Cetani
    View author publications

    You can also search for this author in PubMed Google Scholar

  2. E. Pardi
    View author publications

    You can also search for this author in PubMed Google Scholar

  3. C. Marcocci
    View author publications

    You can also search for this author in PubMed Google Scholar

Corresponding author

Correspondence to F. Cetani.

Ethics declarations

Conflict of interest

The authors declare that they have no conflict of interest.

Ethical approval

This article does not contain any studies with human participants or animals performed by any of the authors.

Informed consent

No need for informed consent.

Funding

This study was not founded by any grant.

Rights and permissions

Reprints and permissions

About this article

Check for updates. Verify currency and authenticity via CrossMark

Cite this article

Cetani, F., Pardi, E. & Marcocci, C. Update on parathyroid carcinoma. J Endocrinol Invest 39, 595–606 (2016). https://doi.org/10.1007/s40618-016-0447-3

Download citation

  • Received:

  • Accepted:

  • Published:

  • Issue Date:

  • DOI: https://doi.org/10.1007/s40618-016-0447-3

Keywords

Search

Navigation